Profile data is unavailable for this security.
About the company
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
- Revenue in EUR (TTM)777.05m
- Net income in EUR-171.37m
- Incorporated2019
- Employees5.01k
- LocationEvotec SEEssener Bogen 7HAMBURG 22419GermanyDEU
- Phone+49 40560810
- Fax+49 4 056081222
- Websitehttps://www.evotec.com/
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price International Ltd.as of 25 Oct 2024 | 9.87m | 5.56% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 5.66m | 3.19% |
| Franklin Templeton Institutional LLCas of 07 Aug 2024 | 5.26m | 2.96% |
| T. Rowe Price Associates, Inc. (IM)as of 27 Sep 2024 | 5.18m | 2.92% |
| Brown Capital Management LLCas of 30 Jun 2024 | 4.49m | 2.53% |
| Allianz Global Investors GmbHas of 31 Jul 2024 | 2.73m | 1.54% |
| Polar Capital LLPas of 30 Sep 2024 | 2.51m | 1.42% |
| Deka Investment GmbHas of 30 Sep 2024 | 2.09m | 1.18% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 2.08m | 1.17% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 1.56m | 0.88% |
